Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
about
Toxicity management of immunotherapy for patients with metastatic melanomaMelanoma immunotherapy dominates the fieldHarnessing the immune system to improve cancer therapyA Mini-Review for Cancer Immunotherapy: Molecular Understanding of PD-1/PD-L1 Pathway & Translational Blockade of Immune CheckpointsThe efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysisImmune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapyThe Immunogenicity of Colorectal Cancer in Relation to Tumor Development and TreatmentThe Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA GuidelinesAdvances in immunotherapy for melanomaUpdates in Therapy for Advanced MelanomaImportance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodiesImmune checkpoint inhibitors: therapeutic advances in melanomaMelanoma: oncogenic drivers and the immune systemCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their InhibitionHistone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune TherapyPembrolizumabThe PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationPD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune ResponsesToxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsThe promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatmentImaging Biomarkers in ImmunotherapyInterstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitorImmune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Robust detection of immune transcripts in FFPE samples using targeted RNA sequencing.Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandDoublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data.Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.Immune checkpoint blockade for hematologic malignancies: a reviewCheckpoint inhibitors in hematological malignanciesA systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanomaClinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitisNuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy.Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trialsPembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure).PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis
P2860
Q26738662-0D919472-81BD-4780-9F5B-3DD4ED5BD5F3Q26738671-11E44416-4721-44E1-AED2-01E32F7972DEQ26738698-E7A8D0A8-7812-4676-BBFF-A304FA2A7754Q26738729-ADD0BF4D-891D-4386-B8FE-708F58DC80ADQ26740280-BC62B62B-CF56-46E4-9897-4E0A96112A22Q26742047-AD144E65-6454-4C68-B8C5-E470457F7801Q26745516-C0115912-792D-435C-9824-46C6D665C1E0Q26745580-C7F58B49-ED42-4988-B170-E3544370361FQ26764792-FF0BD99C-3B16-43BD-B360-4A96C41DFEC2Q26768558-5028A635-24AB-47D9-A155-23DCB4426AA3Q26771119-6FC404FC-6E2E-46F7-A784-DDA333209463Q26775034-136973D0-AC38-46E8-9D2D-92F51CB015ACQ26775591-F022B43B-0F84-4765-BB96-9139E771AAF9Q26775598-2C798808-4769-4856-BBF5-8609701FD553Q26777563-4CDBE6FB-45EB-4DD2-A1D1-77893EA05A11Q26783032-A2637A38-9888-4B17-B56B-77CE638A7170Q26796435-7E3FB0AA-1712-4865-9AAC-4DC941A82618Q28066941-53845571-8F31-40D6-ADA7-97CA1E50645BQ28067141-72574317-C577-48D8-B18B-AC99B963C50BQ28067583-5C4BAAD9-E08A-4C2F-82CE-FC702EF463C2Q28069924-4F64A7FC-1ACB-4679-833D-FC9F2117CD9DQ28076294-1CFBDA82-C06A-4F6A-8BA7-6C165AE8330FQ28079871-0FC62D08-8B38-48CF-ABDC-193E5582B2F0Q28468290-1A262F82-C9B6-4A0E-8B2D-B72EA4D240E6Q30235360-BA1B743F-B3E4-497D-8FCC-DEE8C1CE4B58Q30275870-CAA23769-7DBC-4D67-8EC8-A83F5906E245Q30358368-C29F6304-5ADA-41AB-A24E-C60F8D1DBA19Q30491702-6F24C338-8DC8-40AE-B056-CD353A7A0886Q31014100-EB349CBB-9F31-4199-95AE-859F4C5C9A38Q31171172-61D87927-1C48-4048-B484-F28260E60A4DQ33645590-7D0960E1-F165-4AD7-BF02-E4FAB393F554Q33651495-065FC6A3-6FE9-4BFD-853B-6A591314FFF5Q33775322-923F4401-F835-4865-8EAB-2CDF033366A4Q33813378-283B4A8A-4127-4057-9138-BA5E355A80DBQ33850467-8FB33E4D-3C85-43BB-A13D-FD0C6F5C43A2Q33879794-1EBD5B41-7A52-4CAC-8350-F2BD418C6B1DQ33926135-7B60E16D-46F7-45C3-A463-9FFD99FD0C07Q36001592-541F2A2E-05FD-4D5F-AB5B-B6A12F02DC00Q36024656-1BCF59D9-7B3B-48DE-95BD-6623428AF921Q36092580-1D91D1F0-2C33-4C13-9110-C7BF72AF0E37
P2860
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Pembrolizumab versus investiga ...... ed, controlled, phase 2 trial.
@ast
Pembrolizumab versus investiga ...... ed, controlled, phase 2 trial.
@en
Pembrolizumab versus investiga ...... ed, controlled, phase 2 trial.
@nl
type
label
Pembrolizumab versus investiga ...... ed, controlled, phase 2 trial.
@ast
Pembrolizumab versus investiga ...... ed, controlled, phase 2 trial.
@en
Pembrolizumab versus investiga ...... ed, controlled, phase 2 trial.
@nl
prefLabel
Pembrolizumab versus investiga ...... ed, controlled, phase 2 trial.
@ast
Pembrolizumab versus investiga ...... ed, controlled, phase 2 trial.
@en
Pembrolizumab versus investiga ...... ed, controlled, phase 2 trial.
@nl
P2093
P50
P921
P1433
P1476
Pembrolizumab versus investiga ...... ed, controlled, phase 2 trial.
@en
P2093
Adriane M Zernhelt
Anna C Pavlick
Antoni Ribas
April K S Salama
Carmen Loquai
Christian U Blank
F Stephen Hodi
Igor Puzanov
Jacob Schachter
Jedd D Wolchok
P304
P356
10.1016/S1470-2045(15)00083-2
P50
P577
2015-06-23T00:00:00Z